Open AccessSorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report
Author(s) -
Jingxian Chen,
Chien-Shan Cheng,
Jie Chen,
Lingling Lv,
Xing Shen,
Lan Zheng
Publication year - 2020
Publication title -
journal of international medical research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.421
H-Index - 57
eISSN - 1473-2300
pISSN - 0300-0605
DOI - 10.1177/0300060520964355
Subject(s) - medicine , sorafenib , adenocarcinoma , head and neck , radiation therapy , vascular endothelial growth factor , head and neck cancer , oncology , chemotherapy , vegf receptors , cancer , surgery , hepatocellular carcinoma
The aim of the present study was to report a rare case of head and neck adenocarcinoma with an unknown primary site in a 59-year-old man. After disease progression followed by multiple cycles of chemotherapy and radiotherapy, genetic screening using next-generation sequencing identified vascular endothelial growth factor A amplification and the TP53 R209Kfs mutation. Treatment with the multi-targeted protein kinase inhibitor sorafenib controlled the patient’s symptoms and improved his quality of life.